Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470496 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4765360 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL28781368 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL28472787 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4361492 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL1123659 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4080844 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL30475134 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL2691990 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL2691404 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284233-B | Method for preparing itracin | 浙江湃肽生物股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-114728938-B | Tetrahydroisoquinoline spiro compounds as PRMT5 inhibitors | 南京再明医药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117858872-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-110637025-B | Peptide amide compound, preparation method and medical application thereof | 四川海思科制药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116284233-A | Method for preparing itracin | 浙江湃肽生物股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-114728938-A | Tetrahydroisoquinoline spiro compounds as PRMT5 inhibitors | 江苏先声药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114364682-A | Compound 4,4A,5,7,8, 8A-hexapyrido [4,3-B ] [1,4] oxazin-3-one as MAGL inhibitor | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114364684-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-101501006-A | Pyridone and pyridazinone derivatives as poly (ADP-ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-08-05 | — | — | CN | disclosed |
| CN-101448825-A | CNS active fused bicyclic heterocycle substituted azabicycloalkane derivatives | ABBOTT LAB (US) | 2009-06-03 | — | — | CN | disclosed |
| CN-101291931-A | 9-azabicyclo [3.3.1]nonane derivatives as monoamine reuptake inhibitors | ORGANON NV (NL) | 2008-10-22 | — | — | CN | disclosed |
| WO-2008057938-A1 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| CN-1898239-A | Novel diazaspiroalkanes and their use in the treatment of CCR8 mediated diseases | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | CN | disclosed |
| EP-1626970-A1 | AZABICYCLOALKANE COMPOUNDS AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004106333-A1 | AZABICYCLOALKANE COMPOUNDS AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| CN-1449408-A | Synthetic methods for Aplidine and novel antitumor derivatives, and methods of making and using the same | PHARMA MAR SA (ES) | 2003-10-15 | — | — | CN | disclosed |
| US-5466877-A | Fluorination with deesterification and alkylation | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995025082-A1 | PROCESS FOR CONVERTING PERFLUORINATED ESTERS TO PERFLUORINATED ACYL FLUORIDES AND/OR KETONES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-09-21 | — | — | WO | disclosed |